

Alexander, W. D., Harden, R. McG., Shimmins, J., McLarty, D., and McGill, P. (1967). *Journal of Endocrinology*, 27, 1682.  
 Alexander, W. D., Harden, R. McG., and Shimmins, J. (1968). *Lancet*, 2, 196.  
 Alexander, W. D., Harden, R. McG., McLarty, D., and Shimmins, J. (1969). *Metabolism*, 1, 58.  
 Cassidy, C. E., and VanderLaan, W. P. (1960). *New England Journal of Medicine*, 262, 1228.  
 Chopra, I. J., Solomon, D. H., Johnson, D. E., Chopra, U., and Fisher, D. A. (1970). *Journal of Endocrinology*, 30, 524.  
 Hales, I., Stiel, J., Reeve, T., Heap, T., and Myhill, J. (1969). *Journal of Endocrinology*, 29, 998.

Harden, R. McG., Alexander, W. D., Koutras, D. A., Harrison, M. T., and Wayne, E. (1966). *Journal of Endocrinology*, 26, 397.  
 Koutras, D. A., and Sfontouris, J. (1966). *Journal of Endocrinology*, 35, 135.  
 Morgans, M. E., Oldham, A. K., and Trotter, W. R. (1952). *Journal of Endocrinology*, 8, 250.  
 Stanley, M. M., and Astwood, E. B. (1948). *Endocrinology*, 42, 107.  
 Werner, S. C. (1956). *Journal of Clinical Investigation*, 35, 57.  
 Werner, S. C., Hamilton, H., and Nemeth, M. (1952). *Journal of Endocrinology*, 12, 1561.  
 Werner, S. C., and Spooner, M. (1955). *Bulletin of the New York Academy of Sciences*, 31, 137.

# Urinary Sodium and Potassium Excretion in Fasting Obese Subjects

J. RUNCIE

*British Medical Journal*, 1971, 2, 22-25

### Summary

Data are presented on the urinary excretion of sodium and potassium in 40 obese patients subjected to therapeutic starvation. Two patterns of sodium loss were observed: either a uniform low-level loss or a fluctuating loss leading in some cases to marked sodium depletion. In three patients the response was a combination of these two patterns.

### Introduction

Therapeutic starvation as a significant mode of therapy for the obese patient dates from the observations of Bloom (1959), which were extended by Duncan *et al.* (1962), Drenick *et al.* (1964), and Thompson *et al.* (1966) and which established the validity of this form of treatment. Runcie and Thomson (1970) reviewed the hazards of therapeutic starvation and

drew attention to a hitherto unrecognized danger, the spontaneous development of a renal leak of electrolytes (sodium and potassium), leading to hyponatraemic shock.

With acceptance of the principle of therapeutic starvation interest has become increasingly focused on the mechanisms and adaptive responses necessary to enable man to survive prolonged deprivation of food. Considerable advances have been made in some fields, such as the description by Cahill and his co-workers (Cahill *et al.*, 1966; Felig *et al.*, 1969; Owen *et al.*, 1969) of many essential changes in protein metabolism in fasting.

The purpose of this communication is to present data on the urinary excretion of sodium and potassium in 40 obese patients who had undergone varying periods of therapeutic starvation and to consider the nature of this response and its role in the integrated, adaptive, renal response to starving.

### Methods

The management of obese patients admitted to the wards of the University Department of Materia Medica for therapeutic starvation has been described previously (Thomson *et al.*, 1966). The urine of all patients is collected continuously in

University of Glasgow, Stobhill Hospital, Glasgow N.1  
 J. RUNCIE, M.B., M.R.C.P.GLASG., Lecturer in Materia Medica

TABLE I—Urinary Sodium (mEq/24 hr)

Case No.	Age (years)	Sex	Fast (Day)																			
			1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
1	14	M.	60	62	95	61	25	11	1	0	2	1	2	3	4	5	4	4	3	1	1	2
2	16	F.	109	98	90	122	110	45	13	0	3	8	3	1	0	1	2	1	0	1	1	11
3	28	M.	151	118	106	94	63	59	15	13	14	11	9	15	58	14	31	24	19	24	32	15
4	29	F.	93	65	42	35	28	17	12	40	47	—	—	—	—	44	32	31	36	32	32	
5	31	F.	142	74	51	73	47	27	11	4	4	1	2	2	1	1	1	2	11	13	4	
6	35	F.	43	55	70	74	85	104	95	77	57	31	16	7	11	15	31	19	24	9	18	
7	48	F.	114	114	90	43	16	32	32	78	94	40	36	20	29	20	11	11	25	28	34	
8	47	M.	174	165	—	127	38	120	—	—	6	13	25	40	31	30	30	31	35	21	14	
9	52	F.	120	106	102	68	48	40	29	18	21	17	9	17	17	4	6	11	13	11	6	
10	57	F.	141	52	46	42	52	26	75	6	40	51	68	101	64	30	30	13	4	3	3	

TABLE II—Urinary Sodium (mEq/24 hr)

Case No.	Age (years)	Sex	Fast (Day)																			
			40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59
1	14	M.	Fast ended after 27 days																			
2	16	F.	24	19	11	3	8	2	11	16	17	8	13	29	—	6	3	11	12	17	14	16
3	28	M.	5	6	9	8	5	4	4	6	6	7	6	—	2	6	4	5	6	6	8	6
4	29	F.	90	118	106	138	134	31	130	261	142	34	84	24	36	81	66	142	52	44	44	125
5	31	F.	109	52	34	4	8	17	28	20	18	22	12	15	11	14	8	13	18	39	49	78
6	35	F.	1	2	3	4	11	—	37	25	31	42	41	21	Fast ended		—	—	—	—	—	—
7	48	F.	37	60	60	82	27	29	43	16	5	36	22	50	32	24	11	43	20	48	41	28
8	47	M.	33	34	50	39	—	39	58	47	46	50	47	68	91	39	30	44	47	43	45	32
9	52	F.	9	7	8	8	10	9	6	10	8	7	4	14	5	10	—	—	7	6	11	7
10	57	F.	15	8	3	4	1	3	17	8	15	17	42	45	55	—	21	7	12	7	12	22

TABLE III—Urinary Potassium (mEq/24 hr)

Case No.	Age (years)	Sex	Fast (Day)																			
			1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
1	14	M.	31	20	35	32	35	30	12	7	16	10	—	31	19	28	31	17	14	8	1	2
2	16	F.	39	28	21	30	44	46	36	27	7	19	17	11	9	10	6	12	5	7	9	7
3	28	M.	45	25	23	32	36	38	21	34	24	23	23	29	26	23	34	36	21	21	18	27
4	29	F.	27	36	35	18	34	25	21	18	20	—	—	—	—	—	20	20	20	17	16	16
5	31	F.	25	21	22	35	34	24	18	22	23	12	17	23	15	13	14	14	16	22	25	15
6	35	F.	24	27	26	29	29	24	30	32	30	28	—	18	19	19	24	12	20	10	19	16
7	48	F.	46	40	42	37	26	27	38	22	25	18	18	14	18	13	11	12	14	23	25	27
8	47	M.	52	30	—	28	9	38	—	—	10	23	23	25	23	24	24	23	25	20	26	20
9	52	F.	43	30	28	29	27	51	40	35	27	26	24	26	19	10	13	19	27	18	17	10
10	57	F.	39	20	18	18	19	16	21	8	24	20	27	43	36	24	32	28	9	19	12	9

TABLE IV—Urinary Potassium (mEq/24 hr)

Case No.	Age (years)	Sex	Fast (Day)																				
			40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60
1	14	M.	Fast ended after 27 days																				
2	16	F.	12	9	9	8	8	7	10	14	12	8	6	14	—	8	5	9	6	9	7	9	14
3	28	M.	11	11	11	14	16	13	11	10	10	20	9	—	8	14	12	10	9	13	10	7	9
4	29	F.	20	20	19	30	20	25	23	—	36	22	13	13	8	11	12	19	15	23	19	23	8
5	31	F.	20	14	15	8	8	9	10	7	7	10	8	8	8	7	5	4	4	4	5	5	5
6	35	F.	4	4	4	8	8	—	11	11	14	14	18	13	5	Fast ended		—	—	—	—	—	—
7	48	F.	12	14	10	4	3	11	3	3	2	5	3	3	10	2	9	10	21	20	17	18	
8	47	M.	22	19	35	19	—	13	18	17	15	20	18	25	43	18	17	19	16	20	22	11	
9	52	F.	8	13	18	7	18	9	11	18	11	8	4	14	6	14	—	—	7	6	12	8	
10	57	F.	15	14	20	15	10	6	14	15	18	13	24	23	24	—	14	14	12	9	10	14	

24-hour periods, and an aliquot is analysed for its content of sodium and potassium by standard flame photometer techniques by the same observer (J.R.).

**Results**

In Fig. 1 the age and sex distribution of the patients studied is shown. The urinary excretion of sodium and potassium, respectively, between the 1st and 20th days and between the 40th and 60th days of fasting is shown in Tables I-IV. This is given for 10 patients, two drawn from each of the first five groups in Fig. 1. These periods have been arbitrarily chosen to show the early and late responses in these functions in a significant number of patients.

From the tables a uniform pattern of potassium excretion can be discerned. In the first week of fasting there is an increase, above prefasting levels, in potassium excretion. Thereafter it falls and is maintained at a reduced level—in the range 10 to 20 mEq/day—throughout. With increasing length of fast there is a tendency for potassium excretion to fall further (Fig. 2).

The pattern of urinary sodium excretion is more complex. The most frequent response is that of rapid reduction in urinary sodium excretion and maintenance of this much-reduced level throughout fasting. This is similar to urinary potassium excretion except that greater conservation of sodium is achieved. The response is stable and teleologically

appropriate. It occurred in 25 of the patients in this series. An example of this response is shown in Fig. 3.

In 12 subjects, all females, a different response was seen. It consisted of a pattern of great fluctuation in sodium excretion with daily outputs ranging between 30 and 100 mEq. In some there was continuous fluctuation in sodium excretion, in some there was a cycle of almost regularly recurring peaks of excretion, and in others there was a grossly irregular, seemingly random excretion of sodium. An example of this response is shown in Fig. 4.

In three patients (two males and a female) a third response was seen which appeared to combine features of the first two responses. After a variable but prolonged (>30 days) period of sodium conservation they went on to show a fluctuating sodium loss. This was associated with the loss of the previously established pattern of regular, progressive weight loss (Fig. 5).




FIG. 1—Age and sex distribution of 40 obese, fasting patients.




FIG. 2—Typical urinary potassium excretion in fasting (non-oscillatory).




FIG. 3—Stable urinary sodium excretion in fasting (non-oscillatory).




FIG. 4—Progressive weight loss and oscillatory urinary sodium excretion.




FIG. 5—Urinary sodium excretion in fasting—transitional response—related to irregular weight loss (shaded area).

## Discussion

Daily weight loss in fasting obese subjects averages 0.2 to 0.4 kg. Based on the estimate of a potassium content of intracellular fluid of 151 mEq/l. (Gamble, 1954), and accepting a lower value for adipose tissue, it is clear that urinary potassium excretion in fasting subjects can be derived from the breakdown of fatty tissue and does not involve a change on potassium balance. This is further supported by urinary potassium excretion studies on refeeding. The standard response is that of an immediate reduction in urinary potassium which lasts for a few days only and thereafter rises rapidly to normal levels. If a significant potassium deficit had been incurred during fasting the appropriate renal response would be a period of conservation directly related to the size of the deficit incurred. The increased potassium excretion in the first week of fasting has been shown to be due to increased gluconeogenesis from excessive utilization of lean body mass and is associated with a raised urinary nitrogen loss (Felig *et al.*, 1969).

Sodium homeostasis in fasting obese subjects is a more complex response. This is to be expected since a multiplicity of hormones and factors, both renal and extrarenal, are known to affect urinary sodium excretion. The relationship between sodium balance and blood pressure is a further complex variable influencing this situation. The investigation of a dynamic control system of this complexity presents great problems. A possible approach is suggested below.

The role of the kidney as the regulator of the internal environment has been incontrovertibly established for over a century. In fasting subjects, after the cessation of bowel evacuation, the kidneys become the sole, major excretory organ for the body—that is, the urinary output of such patients reflects the metabolic changes necessary to maintain homeostasis. The further consequence of the biological importance of sodium is that its loss or elimination from the system—in fasting subjects—is a highly controlled response.

To analyse these responses (Figs. 3 and 4) it is logical to turn to control system theory to attempt to explain them. It can be shown mathematically that in any system in which there is feedback control of function the probability of oscillatory behaviour approaches unity with increasing complexity of control system (T. Wheldon, personal communication, 1970). This response is typical of many biological systems, and the likelihood of oscillatory behaviour occurring there was deduced by Morowitz (1966). This has led to the increasing recognition of the response in biological systems, in particular in the recovery of red cells after marrow irradiation (Kirk *et al.*, 1968). In physiological or steady-state conditions the response is a latent property. Under stress the response of the system alters, and it is in this phase of altered activity that oscillatory behaviour may manifest itself.

Urinary sodium excretion in fasting is a further example of oscillatory behaviour response in biological systems. It must be stressed that the common response is not oscillatory, and when peaks of excretion occur these appear to be rapidly damped out. In 12 patients the response is oscillatory of variable complexity. The possibility of this response being artefactual, induced by surreptitious eating, is considered and dismissed. Such patients are ketotic throughout fasting, indicating continuous metabolism of adipose tissue. Most importantly, this fluctuating sodium loss is associated with regular progressive weight loss rather than the irregular pattern of weight loss induced by surreptitious eating (Fig. 4). It is clear that these oscillations are generated by metabolic requirements not related to fasting. In some patients the response appears to be triggered by an expansion in extracellular volume, as evidenced by irregular weight loss and/or fluid retention, suggesting the action of a threshold controlling effect (Fig. 5).

The problem of the origin of the urinary sodium response cannot be derived from the breakdown of adipose tissue and becomes a charge on sodium balance. It can arise from an existing body pool or reserve such as that in bone by a reduction in extracellular fluid. Another possibility is that the fall in blood pressure, which occurs in all fasting subjects (Runcie and Thomson, 1970), in some unknown way releases sodium.

The analysis of the urinary sodium excretory response in fasting is clearly of importance. The complexity is such that this can probably be approached only by deriving a mathematical model of the integrated behaviour of the whole system and using this to explore and define the interrelationships of the numerous functions which control sodium excretion.

I wish to thank Professor S. Alstead and Professor A. Gold for permission to study patients under their care, Mr. T. White for much helpful discussion and mathematical guidance, and P. Waldie and the department of medical photography and graphic design at Stobhill Hospital, for preparing the illustrations.

## References

- Bloom, W. L. (1959). *Metabolism*, 8, 214.
- Cahill, G. F., jun., *et al.* (1966). *Journal of Clinical Investigation*, 45, 1.
- Drenick, E. J., Swendseid, M. E., Bland, W. H., and Tuttle, S. G. (1967). *Journal of the American Medical Association*, 187, 100.
- Duncan, G. G., Frazer, R. I., and Cristofori, F. C. (1962). *Journal of the American Medical Association*, 181, 309.

Felig, P., Owen, O. E., Wahren, J., and Cahill, G. F., jun. (1969). *Journal of Clinical Investigation*, 48, 584.

Gamble, J. L. (1954). *Chemical Anatomy, Physiology and Pathology of Extracellular Fluid*, 6th Edn. Cambridge, Massachusetts, Harvard University Press.

Kirk, J., Orr, J. S., and Hope, C. S. (1968). *British Journal of Haematology*, 15, 35.

Morowitz, H. J. (1966). *Journal of Theoretical Biology*, 13, 60.

Orr, J. S., Kirk, J., Gray, K. G., and Anderson, J. R. (1968). *British Journal of Haematology*, 15, 23.

Owen, O. E., Felig, P., Morgan, A. P., Wahren, J., and Cahill, G. F., jun. (1969). *Journal of Clinical Investigation*, 48, 574.

Runcie, J., and Thomson, T. J. (1970). *British Medical Journal*, 3, 432.

Thomson, T. J., Runcie, J., and Miller, V. (1966). *Lancet*, 2, 992.

## Controlled Trial of Metoclopramide in the Treatment of Flatulent Dyspepsia

A. G. JOHNSON

*British Medical Journal*, 1971, 2, 25-26

### Summary

A double-blind cross-over trial of metoclopramide (Maxolon) against placebo was undertaken in 42 patients with flatulent dyspepsia. A highly significant difference was found in favour of the active drug ( $P < 0.01$ ). The time at which the drug is given in relation to the meal and onset of symptoms is probably important. It is concluded that metoclopramide is effective in the short-term treatment of these symptoms but should be started only after thorough investigations have excluded more serious disease.

### Introduction

Flatulent dyspepsia is a well-known symptom complex occurring in association with cholelithiasis when it may persist after cholecystectomy (Maingot, 1956; Bodvall, 1964), but it has been found with equal frequency in patients with a normal cholecystogram (Price, 1963). It has been defined by Rhind and Watson (1968) as follows: "Epigastric discomfort after meals, a feeling of fullness so that tight clothing is loosened, eructation with temporary relief, and regurgitation of sour fluid to the mouth with heartburn." The cause of these symptoms is not known but they are possibly associated with abnormal gastrointestinal motility, leading to regurgitation of duodenal juice into the stomach (Capper *et al.*, 1967) and delayed gastric emptying.

Metoclopramide increases the strength of gastric antral contractions and speeds gastric emptying, when measured radiologically (Kreel, 1970) or by a dye dilution method (Connell and George, 1969); this effect is still observed after vagotomy (Banke, 1968). It appears to relax the duodenal cap (Jacoby and Brodie, 1967) and cause duodenal contractions to follow those of the antrum if they were previously out of phase (Johnson, 1971), and would, therefore, tend to prevent pyloric regurgitation. It acts by enhancing the local effect of acetylcholine on the gastric smooth muscle (Eisner, 1968), and it also has a central antiemetic effect. It would seem, on theoretical grounds, a suitable drug with which to treat flatulent dyspepsia and has been found to be effective in practice in France and in two preliminary trials in Britain (Boisson and Albot, 1966; Trafford *et al.*, 1967; Marshall, 1970).

### Patients and Methods

**Selection of Patients.**—Consecutive patients attending a gastroenterological clinic were admitted to the trial if they complained only of flatulent dyspepsia as defined above. They came from three clinical groups: (1) Those with radiograph negative dyspepsia (normal barium meal and cholecystogram), but including some patients with a small hiatus hernia; (2) Those with persistent flatulent dyspepsia after cholecystectomy; and (3) Those with these symptoms after vagotomy and pyloroplasty or pyloroplasty alone.

**Plan of Trial.**—A double-blind cross-over trial was devised of metoclopramide against placebo, each patient being used as his own control. Metoclopramide was given as 10-mg tablets three times a day, the placebo and active tablets being given for two weeks each. This comparatively short period was chosen to avoid the natural fluctuation of the symptoms that tends to occur over the months. If patients were already on treatment for the symptoms with drugs other than antiacids a week without drugs was allowed before the trial began. Because metoclopramide probably has a fairly short duration of action it was given just before the meal to patients whose symptoms occurred during or soon after the meal (up to 45 minutes), and after the meal to those whose symptoms occurred one hour or more after food. The patient was supplied with separate containers for each of the four weeks.

**Method of Assessment.**—The flatulent dyspepsia syndrome was divided into nine individual symptoms: belching; full feeling after normal meals; inability to finish meals; abdomen becomes distended, clothes have to be loosened; burning discomfort in epigastrium; burning discomfort in chest (heartburn); bitter fluid in mouth; nausea; and vomiting. The patients were seen before the trial, and each symptom was recorded as absent, mild, or severe. They were asked to note how these symptoms changed each week. They were told that two types of tablet, which looked identical, were being tried to see which was better. At the end of four weeks they were interviewed again and the degree of symptoms during each week was recorded. Finally, they were asked which two weeks were better. Most stated without hesitation that either the first two or the second two weeks were better, but some said that all the weeks were equally good and some that none of the tablets made any difference. Others stated that either the first and fourth or second and third weeks were better, clearly showing no difference between active drug and placebo. A more complicated arbitrary scoring system involving the types of food eaten was abandoned as it was thought to introduce more observer bias. At least once during each week of the trial the patients were told to try some food known to produce symptoms.

Charing Cross Hospital Medical School, Fulham Hospital, London W6 8RF

A. G. JOHNSON, F.R.C.S., Lecturer in Surgery